AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
243.41B
Market cap243.41B
Price-Earnings ratio
23.29
Price-Earnings ratio23.29
Dividend yield
1.68%
Dividend yield1.68%
Average volume
2.59M
Average volume2.59M
High today
$157.95
High today$157.95
Low today
$154.81
Low today$154.81
Open price
$156.76
Open price$156.76
Volume
2.26M
Volume2.26M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$153.41
52 Week low$153.41

Stock Snapshot

The current AstraZeneca(AZN) stock price is $159.30, with a market capitalization of 243.41B. The stock trades at a price-to-earnings (P/E) ratio of 23.29 and offers a dividend yield of 1.68%.

As of 2026-10-06, AstraZeneca(AZN) stock has fluctuated between $154.81 and $157.95. The current price stands at $159.30, placing the stock +2.9% above today's low and +0.9% off the high.

The AstraZeneca(AZN)'s current trading volume is 2.26M, compared to an average daily volume of 2.59M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $153.41.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $153.41.

AZN News

Seeking Alpha 12h
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from pr...

AstraZeneca CEO Soriot says drugmaker can grow without big acquisition
CNBC 13h
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Key Points AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "f...

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
TipRanks 17h
AstraZeneca opens R&D center in Cambridge, Massachusetts

AstraZeneca (AZN) today announced the opening of its newest global strategic research and development center, in Kendall Square, Cambridge, Massachusetts. The n...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More AZN News

TipRanks 21h
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca, with a price target of p16,500.00. Sachin Jain...

TipRanks 22h
AstraZeneca completes $2B equity investment in Summit Therapeutics

Summit Therapeutics (SMMT) announced the successful closing of AstraZeneca’s (AZN) strategic equity investment in Summit. The equity investment will support con...

TipRanks 22h
AstraZeneca invests $2bn in Summit to accelerate bispecific and ADC cancer portfolio

AstraZeneca ( (GB:AZN) ) has provided an update. AstraZeneca has completed a $2 billion equity investment in Summit Therapeutics, strengthening its position in...

Simply Wall St 2d
Summit Therapeutics Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?

AstraZeneca, Daiichi Sankyo and Summit Therapeutics (SMMT) have agreed to test Datroway with ivonescimab in multiple cancers, beginning with a Phase III trial i...

Summit Therapeutics Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?
TipRanks 4d
Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

Summit Therapeutics (SMMT) announced a clinical trial collaboration agreement with Daiichi Sankyo (DSNKY) and AstraZeneca (AZN) to evaluate ivonescimab, a novel...

Benzinga 6d
Summit Therapeutics Stock Climbs Wednesday: What's Happening?

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) moved higher in Wednesday afternoon trading, extending gains from the previous session following a landmark $2...

Summit Therapeutics Stock Climbs Wednesday: What's Happening?
24/7 Wall St. 6d
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine wh...

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.